US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals Inc (MACK) ニュース

MACK

Merrimack Pharmaceuticals (MACK)

Merrimack Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MACK

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/11	05 : 45	Edgar (US Regulatory)	Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/11	05 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/11	05 : 30	Business Wire	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/09	20 : 45	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/09	20 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/09	20 : 30	Business Wire	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/05/01	06 : 15	Business Wire	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/28	05 : 30	Business Wire	Merrimack Receives $225 Million Milestone Payment from Ipsen	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/08	06 : 42	Edgar (US Regulatory)	Form 425 - Prospectuses and communications, business combinations	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/08	06 : 39	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/08	06 : 30	Business Wire	Merrimack Reports Full Year 2023 Financial Results	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/08	06 : 15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/08	02 : 29	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/03/06	06 : 44	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/23	06 : 46	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/15	06 : 20	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/14	06 : 26	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/14	06 : 22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/14	06 : 18	Business Wire	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/02/01	04 : 08	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2024/01/26	06 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/12/29	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/12/14	06 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/12/12	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/11/21	08 : 59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/11/17	07 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/11/03	05 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/11/03	05 : 30	Business Wire	Merrimack Reports Third Quarter 2023 Financial Results	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/08/15	05 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:MACK	Merrimack Pharmaceuticals Inc
2023/08/10	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MACK	Merrimack Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:MACK

1 2 3 4 5 6 7 8 9 10 次へ >>

Richard Bernstein Adviso...

Orron Energy AB (PK)

PointPay Crypto Banking Token V2

Xgermany 2d �

Xutrea 7 -10 1d

Medicus Sciences Acquisi...

Vontobel Financial Produ...

Smart Trust California M...

iShares MSCI Europe IMI ...

Citigroup Global Markets...

ELETE43 Ex:41,18

Orange Sa FLR Med.-T. Nt...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約